ImmunoCellular's lead drug is a cancer immunotherapy, ICT-107, under development as a treatment for glioblastoma multiformae, a form of brain tumor. Updated data from a phase I trial in 16 patients treated with ICT-107 showed a four-year survival rate of 50%, with 38% of patients reporting no tumor growth for 48-66 months. These new data were reported at the ASCO meeting last week.
The company claims these results compare very favorable to an "historic" mean overall survival of 12% after four years.
Be skeptical when a company compares data from a single-arm trial to "historic" results, particularly a single-arm trial of only 16 patients, all enrolled by the same investigator at a single hospital.
Unless a clinical trial directly compares an experimental therapy to a placebo or some other control -- something ImmunoCellular did not do in the phase I study of ICT-107 -- an observation of a survival benefit cannot be determined. The ICT-107 data look promising but that may disappear completely when larger, randomized trials are conducted.ImmunoCellular is running a larger, randomized phase II study of ICT-107 versus a placebo in glioblastoma multiformae patients. Interim results from this study are expected in the first quarter 2013. ImmunoCellular's fully diluted share count (including options and warrants) is approximately 55 million. At $3.70 per share, the company's market value of $204 million isn't cheap. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV